The safety and efficacy of RAD001 in treating patients with subependymal giant cell astrocytoma (SEGA) associated with Tuberous Sclerosis Complex (EXIST1)

This is a randomised, double-blind, placebo-controlled trial investigating the safety and efficacy of the drug RAD001in treating SEGAs (brain tumours) in patients with the genetic disorder Tuberous Sclerosis Complex.  This trial is also investigating the effect of the drug on patients' kidney tumours, seizures, and neuropsychological performance.

This study runs at centres worldwide, and is led in the UK by Dr Finbar O'Callaghan.

Novartis Pharmaceuticals has funded this project.

Further information about the study is available at clinicaltrials.gov.

Further information about Tuberous Sclerosis:

The Tuberous Sclerosis Association - the UK charity that supports individuals, promotes awareness, and seeks the causes and best possible management of Tuberous Sclerosis Complex (TSC).